A major goal of Wisconsin ADRC investigators is to identify AD prior to the onset of clinical symptoms. In order to do this we rely on studies in people who have certain risk factors for AD including known genetic risks factors, family history of dementia, cardiovascular risk factors, and emerging cognitive complaints or mild symptoms. Several studies are ongoing in this area.
We participate in a number of multisite and single site clinical trials in which brain imaging is employed as a surrogate outcome marker. One of these studies is the Alzheimer’s Disease NeuroImaging Initiative or ADNI. To find out more about how to participate in a clinical trial for AD at the University of Wisconsin visit WADRC.
The human microbiome is the group of bacteria and fungi that make their home in or on your body. Some of those that live in your gut do helpful things like help you digest food and fight off the harmful bacteria, while others just find it a comfy place to live. What is in the gut inevitably gets flushed down the toilet, so fecal samples can tell us your unique microbiome. This study seeks to understand the human microbiome, specifically in the gut, and how it may be different for those with Alzheimer’s Disease.
The University of Wisconsin ADRC is one of 60 sites participating in ADNI. This study is currently the largest public-private partnership between NIH, the Alzheimer’s Association and industry. The goal of this study is to determine whether imaging of the brain every 6-12 months can help predict the onset and monitor the progression of dementia due to AD. By gaining a thorough understanding of how the brain changes over time in AD, scientists will be able to design future treatment studies to slow down the rate of change in the brain itself. The imaging methods include Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans. In addition to neuroimaging, the study examines blood, and, cerebrospinal fluid to determine if biomarkers can predict and monitor the disease. The University of Wisconsin is participating in all arms of the study including 3T MRI, amyloid plaque PET imaging and neurofibrillary tangle PET imaging.
There are multiple open studies at any point in time in our larger research program at The Wisconsin Alzheimers Disease Research Center. Interested participants are encouraged to click here to learn more.